Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
Follow SPRB
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
(16.23) | (12.27) | (14.65) | (8.21) |
+8 more quarters Free account |
Depreciation & Amortization |
0.63 | 0.25 | 0.01 | 0.00 | |
Non Cash Items (Other) |
0.33 | 0.85 | 5.78 | 0.59 | |
Accounts Payable Change |
(1.43) | 1.70 | (0.44) | 0.58 | |
Change in payables and accrued liability |
(0.59) | (1.30) | 1.81 | 1.09 | |
Change in other assets and liabilities |
(4.83) | 2.03 | 1.04 | 0.64 | |
Operating Cash Flow |
(22.12) | (8.73) | (6.46) | (5.32) | |
Capital expenditures |
(0.13) | (0.01) | — | — | |
Investing cash flow |
(0.13) | (0.01) | — | — | |
Repayment/Issuance of Debt (Net) |
0.00 | 14.15 | (0.84) | (0.40) | |
Equity Repurchase (Common, Net) |
69.00 | — | 50.07 | 0.00 | |
Other financial activities |
(4.53) | (0.23) | (4.53) | — | |
Financing cash flow |
64.47 | 13.92 | 44.69 | (0.40) | |
Change in Cash |
42.22 | 5.17 | 38.24 | (5.72) | |
Beginning Cash |
0.00 | 48.94 | 0.00 | 0.00 | |
Ending Cash |
42.22 | 54.12 | 38.24 | (5.72) | |
Stock Based Compensation |
0.87 | 0.69 | 1.69 | 0.42 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(6.85) | 2.43 | 2.41 | 2.31 | |
Issuance/Purchase of Shares |
69.00 | — | 50.07 | 0.00 |